CN102106891B - Cardio-cerebral refreshing sustained-release soft capsules and preparation method thereof - Google Patents
Cardio-cerebral refreshing sustained-release soft capsules and preparation method thereof Download PDFInfo
- Publication number
- CN102106891B CN102106891B CN2009102639095A CN200910263909A CN102106891B CN 102106891 B CN102106891 B CN 102106891B CN 2009102639095 A CN2009102639095 A CN 2009102639095A CN 200910263909 A CN200910263909 A CN 200910263909A CN 102106891 B CN102106891 B CN 102106891B
- Authority
- CN
- China
- Prior art keywords
- parts
- sustained
- vitamin
- heart
- release coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Abstract
The invention discloses cardio-cerebral refreshing sustained-release soft capsules and a preparation method thereof. The sustained-release soft capsules contain capsule shells and contents, wherein the contents contain the following active pharmaceutical ingredients in mass ratio: 390 parts of safflower oil, 3 parts of borneol, 17 parts of vitamin E and 65 parts of vitamin B; and the contents contain the following raw materials in parts by weight: 4.15 parts of active pharmaceutical ingredients and 2-8 parts of sustained-release coating material, wherein the sustained-release coating material is one or mixture of polyethylene glycol (PEG) and glyceryl monostearate based on an arbitrary proportion. The preparation method mainly comprises the following steps: grinding and evenly mixing 1/2-2/3 of the safflower oil in the active pharmaceutical ingredients and the other active pharmaceutical ingredients, and then, grinding and evenly mixing the residual safflower oil, the sustained-release coating material and a dispersing agent or a diluting agent; and evenly mixing the two obtained mixtures, and sieving with a 80-100 mesh sieve to obtain the capsule contents. The sustained-release soft capsules provided by the invention have the advantages that drug release can keep uniform and constant, drug action time can be prolonged, and a peak valley phenomenon can be avoided.
Description
Technical field
The present invention relates to pharmaceutical preparation and preparation method thereof, specifically a kind of slow releasing preparation that contains active ingredient of Chinese herbs and preparation method thereof.
Background technology
Xinnaoqing soft capsules be a kind of be main Chinese medicine and western medicine compound formulation with Chinese medicine.Active constituents of medicine in the Xinnaoqing soft capsules is safflower oil, Borneolum Syntheticum, vitamin E, vitamin B
6Its consumption proportion is 390 parts of safflower oils, 3 parts of Borneolum Syntheticums, 17 parts of vitamin Es, vitamin B
65 parts.Containing multiple human body in the safflower oil in this active constituents of medicine can't self synthetic essential unsaturated fatty acid.It not only can cholesterol reducing but also can combine with cholesterol, reduces the deposition of cholesterol in blood vessel wall, effectively prevents and treats hypertension, hyperlipemia, atherosclerosis, coronary heart disease, angina pectoris and apoplectic hemiplegia sequela; Borneolum Syntheticum has causing resuscitation with aromatic drugs, refreshment effect, can recover nervous function, the obnubilation that treatment cerebral arteriosclerosis, brain atrophy, apoplexy sequela cause, forgetful, dementia etc.; Vitamin B
6Participate in three major nutrient sugar, fat, proteinic metabolism in the body, anti-artery blood vessel wall necrosis, come off, prevent thrombosis, prevention of arterial is atherosis, the generation of cerebral thrombosis, myocardial infarction; A large amount of vitamin Es protect vitamin A, vitamin C and fatty acid to exempt from destruction in human body, make cell complete, and can suppress the formation of free radical, and enhancing human immune reduces disease, slow down aging.
The function of Xinnaoqing soft capsules cures mainly and is promoting blood circulation to remove blood stasis, inducing menstruation to relieve menalgia, the refreshment of having one's ideas straightened out.Clinical apoplexy, the apoplex involving the channels and collaterals that is usually used in due to the stagnation of blood stasis, hemiplegia, facial hemiparalysis, obstruction of qi in the chest and cardialgia, cerebral infarction, coronary heart disease, diseases such as angina pectoris and hyperlipemia.Because Xinnaoqing soft capsules has the adverse drug of covering abnormal smells from the patient, facilitates patients, therefore receive the favor of clinical patients deeply.But there are weak points such as active constituents of medicine is easy also to be eliminated by the human body fast Absorption, and plasma half-life is short, and blood drug level rises and falls greatly, and peak valley phenomenon is obvious in this capsule, has influenced the therapeutic effect of medicine thus.
Summary of the invention
The object of the invention is exactly the problem that will discharge soon and be difficult to control constant slow release to existing Xinnaoqing soft capsules ubiquitous early stage; Provide a kind of can even constant drug release rate, prolong drug action time, avoid peak valley phenomenon, help guaranteeing the clear slow release soft capsule of heart and brain of drug effectiveness and safety; A kind of method for preparing of this medicine is provided simultaneously.
The objective of the invention is to realize like this:
The clear medicament slow release soft capsule of heart and brain provided by the present invention includes softgel shell and content, and the medicament active composition in the content is to be 390 parts of safflower oils by mass ratio, 3 parts of Borneolum Syntheticums, 17 parts of vitamin Es, vitamin B
65 parts of formations, content comprises the raw material of following weight part ratio:
4.15 parts of active constituents of medicine, 2～8 parts of sustained release coating materials; Said sustained release coating material is the mixture of a kind of or the two arbitrary proportion in Polyethylene Glycol, the glyceryl monostearate;
Its preferred proportion is 4.15: 3～6.In the preferred proportion scope, its slow release effect is more obvious.
Slow release soft capsule of the present invention, its content are preferably in the said ratio scope, to be added with 0.5～3 part dispersant or diluent again.
That is: the clear active constituents of medicine of heart and brain is 4.15 parts, 2～8 parts of sustained release coating materials, 0.5～3 part of dispersant or diluent.
Its more preferred weight part ratio is:
1～2 part of 4.15 parts of the clear active constituents of medicine of heart and brain, 3～6 parts of sustained release coating materials, dispersant or diluent.
Dispersant wherein can be selected one or more mixture in ethyl cellulose, sodium carboxymethyl cellulose, acrylic resin, hypromellose, polyvinylpyrrolidone, carbopol, the Cera Flava for use, but a kind of in the preferably polyethylene ketopyrrolidine, carbopol, Cera Flava.
As select diluent, can select a kind of in soybean oil, Semen Maydis oil, the Oleum Arachidis hypogaeae semen.
In capsule casing material, the present invention adds gel skeleton substrate, with the further releasing effect that improves medicament active composition.
Said gel skeleton substrate can be selected a kind of in hydroxypropyl methylcellulose, polyvinylpyrrolidone, the water-soluble chitosan for use.
The clear medicament slow release preparation of soft capsule of the heart and brain that the present invention provides simultaneously method, it may further comprise the steps:
(a) press mass ratio, take by weighing active constituents of medicine: 390 parts of safflower oils, 3 parts of Borneolum Syntheticums, 17 parts of vitamin Es, vitamin B
65 parts.
(b) capsule 's content comprises the raw material of following weight part ratio: 0.5～3 part of 4.15 parts of active constituents of medicine, 2～8 parts of sustained release coating materials, dispersant or diluent;
Wherein dispersant is a kind of in polyvinylpyrrolidone, carbopol, the Cera Flava, and diluent is a kind of in soybean oil, Semen Maydis oil, the Oleum Arachidis hypogaeae semen;
(c) safflower oil with 1/2～2/3 in active constituents of medicine amount grind with the other drug active component, mixing, with the safflower oil of surplus and sustained release coating material and dispersant or diluent grinding, mixing; With the two mixing, cross 80～100 mesh sieves again, process capsule 's content;
(d) preparation softgel shell: earlier with the gelatin fusing, press 1: 0.05～1.0 mass ratio again, in gelatin, add hydroxypropyl methylcellulose, polyvinylpyrrolidone or water-soluble chitosan, stir;
(e) with above-mentioned softgel shell with content compacting or drip and be made as soft capsule.
Experiment showed, medicine of the present invention, its medicament active composition discharges constant, avoided peak valley phenomenon, and side effect is little.Because medicining times is few, and injection volume is little, and is easy to use,, needing to be particularly useful for the cardio-cerebral vascular disease patient of long-term prescription simultaneously so patient's compliance is good.
Adopt the clear medicament slow release soft capsule of heart and brain of the inventive method preparation, effect is even more ideal.Realized both initial release amounts of may command thus, can guarantee simultaneously that again the final release of active constituents of medicine is complete.
The selection of the consumption proportion among the present invention; Can slowly discharge after making the active constituents of medicine arrival gastrointestinal tract in the capsule 's content for absorption; Thereby even constant blood drug level and necessary long period of treatment have been kept; And avoid peak valley phenomenon, guaranteed the effectiveness and the safety of drug use thus.
Description of drawings
Fig. 1 is average blood drug level-time plot that the Beagle dog is taken slow release soft capsule of the present invention, two kinds of preparations of common soft capsule.
Below through specific embodiment the present invention is made further detailed description.
The specific embodiment
Embodiment 1: 1000 of the clear slow release soft capsules of preparation heart and brain.
(a) take by weighing safflower oil 390g, Borneolum Syntheticum 3g, vitamin E 17g, vitamin B
65g; Glyceryl monostearate 300g, soybean oil 100g;
(b) with 260g safflower oil and Borneolum Syntheticum, vitamin B
6, vitamin E, grind mixing in the lump; With the safflower oil of surplus and glyceryl monostearate, soybean oil grind, mixing; With the two mixing, cross 80～100 mesh sieves again, process capsule 's content;
(c) preparation softgel shell: earlier with the fusing of 1000g gelatin, in gelatin, add the 50g hydroxypropyl methylcellulose, stir;
(d) with above-mentioned softgel shell with content compacting or drip and be made as soft capsule, ball is washed in typing, oven dry promptly gets.
Made slow release soft capsule can reach after discharging one hour that zero level discharges and effective slow release.
Embodiment 2: 1000 of preparation Xinnaoqing soft capsules.
(a) take by weighing supplementary material:
Safflower oil 390g, Borneolum Syntheticum 3g, vitamin E 17g, vitamin B
65g, PEG400 400g, ethyl cellulose 70g, Cera Flava 50g;
(b) with 195g safflower oil and Borneolum Syntheticum, vitamin B
6And vitamin E, grind mixing in the lump;
(c) safflower oil and ethyl cellulose, the Cera Flava with surplus grind in the lump, mixing; With the two mixing, cross 100 mesh sieves again, process capsule 's content;
(d) preparation softgel shell: earlier with the fusing of 1000g gelatin, in gelatin, add the 500g polyvinylpyrrolidone, stir;
(e) with above-mentioned softgel shell with content compacting or drip and be made as soft capsule, ball is washed in typing, oven dry promptly gets.
Slow release soft capsule in-vitro release rate described in this instance is higher, but release in 10 hours is complete.
Embodiment 3:
(a) take by weighing supplementary material:
Safflower oil 390g, Borneolum Syntheticum 3g, vitamin E 17g, vitamin B
65g, PEG400 260g, polyvinylpyrrolidone 80g, hypromellose 90g;
(b) with 195g safflower oil and Borneolum Syntheticum, vitamin B
6, vitamin E, grind mixing in the lump;
(c) with the safflower oil of surplus and PEG400, polyvinylpyrrolidone, hypromellose grind, mixing;
(d) b step, c made mixture of step, mixing is crossed 100 mesh sieves, processes capsule 's content;
(d) preparation softgel shell: earlier with the fusing of 1000g gelatin, in gelatin, add the 500g water-soluble chitosan, stir;
(e) with above-mentioned softgel shell with content compacting or drip and be made as soft capsule, ball is washed in typing, oven dry promptly gets.
Embodiment 4: the drug release contrast experiment.
1, the assay method of slow release index substance vitamin E:
[release degree] measured according to HPLC (2005 editions appendix VID of Chinese Pharmacopoeia).
Chromatographic condition and system suitability use octadecylsilane chemically bonded silica to be filler, and methanol is mobile phase, detect wavelength 285nm, and number of theoretical plate is not less than 2500 by the vitamin E peak.
It is an amount of that the preparation precision of reference substance solution takes by weighing the vitamin E reference substance, adds 0.5% Tween solution and process the solution that every 1ml contains 20 μ g, promptly gets.
These article are got in the preparation of need testing solution, and according to drug release determination method (appendix XD first method), adopting dissolution method first subtraction unit (appendix XC) is release medium with 0.5% tween 900ml; Rotating speed is that per minute 100 changes; Solution 5ml was got in operation respectively in the time of 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours in accordance with the law, filtered; And supplementing water 5ml in stripping rotor immediately, get subsequent filtrate respectively.
Algoscopy: accurate respectively reference substance solution and each 20 μ l of need testing solution of drawing, inject chromatograph of liquid, measure, calculate every burst size respectively at different time.
2, experiment comparing result (seeing table 1, table 2, table 3 for details)
Table 1 embodiment 1 made slow release soft capsule and common Xinnaoqing soft capsules preparation medicine discharge contrast
| Time (hour) | Mill run VE% | Embodiment 1 product VE% |
| 0 | 0 | 0 |
| 1 | 38.2±2.6 | 29.6±3.8 |
| 2 | 67.3±3.7 | 37.9±6.3 |
| 4 | 96.2±4.9 | 50.2±5.2 |
| 6 | 98.7±3.2 | 71.3±2.3 |
| 8 | 99.8±5.1 | 86.5±4.7 |
| 10 | 99.4±3.8 | 98.7±4.0 |
Table 2 embodiment 2 made slow release soft capsules and common Xinnaoqing soft capsules preparation medicine discharge contrast
| Time (hour) | Mill run | Embodiment | 2 product VE% |
| 0 | 0 | 0 | |
| 1 | 38.2±2.6 | 31.7±5.3 | |
| 2 | 67.3±3.7 | 45.8±4.2 | |
| 4 | 96.2±4.9 | 63.5±3.2 | |
| 6 | 98.7±3.2 | 82.7±2.7 | |
| 8 | 99.8±5.1 | 97.4±3.8 | |
| 10 | 99.4±3.8 | 100.2±3.2 |
Table 3 embodiment 1 made slow release soft capsule and common Xinnaoqing soft capsules preparation medicine discharge contrast
| Time (hour) | Mill run | Embodiment | 3 product VE% |
| 0 | 0 | 0 | |
| 1 | 38.2±2.6 | 27.6±4.4 | |
| 2 | 67.3±3.7 | 40.2±4.8 | |
| 4 | 96.2±4.9 | 55.7±4.2 | |
| 6 | 98.7±3.2 | 72.3±2.7 | |
| 8 | 99.8±5.1 | 85.4±3.1 | |
| 10 | 99.4±3.8 | 99.7±5.0 |
The common Xinnaoqing soft capsules preparation of being selected for use in the above-mentioned experiment, commercially available Xinnaoqing soft capsules (manufacturer: Shineway Pharmaceutical Co., Ltd).
Can find out that from above-mentioned experiment medicine of the present invention can be kept even constant blood drug level and the height release degree that keeps the long period.
Embodiment 5: the body giving drugs into nose is for dynamic test.
By clear slow release soft capsule of heart and brain and the common Xinnaoqing soft capsules that embodiment 3 makes, the Beagle dog is the single oral dose administration respectively, estimates slow releasing preparation of the present invention at the intravital pharmacokinetics of dog.
6 of Beagle dogs are divided into two groups at random, and three every group, the male and female dual-purpose, fasting 16 hours, the clear slow release soft capsule of heart and brain that the oral embodiment 3 of test group makes, the oral common Xinnaoqing soft capsules of matched group, dosage are one/, taking medicine gives suitable quantity of water simultaneously.After administration, got blood 2ml in 1,2,4,6,8,10,12,16,24 hour, put in the heparinization test tube,, get upper plasma and place one 20 ℃ of refrigerators subsequent use with the 3000rpm centrifugalize.The concentration of vitamin E is measured with the HPLC method in the blood, and chromatographic condition is with external drug release determination condition.
Result of the test:
Mean plasma concentration-time graph is seen Fig. 1.
The body giving drugs into nose is seen table 4 for kinetic parameter.
The body giving drugs into nose is for kinetic parameter (ng/ml) after table 4 administration
Can find out that from Fig. 1 and table 4 slow release soft capsule of the present invention is compared with common soft capsule, blood drug level rises slowly, and concentration change is steady, and drug release time obviously postpones, and UD concentration significantly reduces, and has obvious slow release characteristic, and bioavailability improves.
Claims (6)
1. clear medicament slow release soft capsule of heart and brain, it is made up of softgel shell and content, and the medicament active composition in the content is to be 390 parts of safflower oils by mass ratio, 3 parts of Borneolum Syntheticums, 17 parts of vitamin Es, 5 parts of formations of vitamin B6, it is characterized in that
Content comprises the raw material of following weight part ratio:
4.15 parts of active constituents of medicine, 0.5～3 part of 2～8 parts of sustained release coating materials, dispersant or diluent; Said sustained release coating material is the mixture of a kind of or the two arbitrary proportion in Polyethylene Glycol, the glyceryl monostearate;
Softgel shell is prepared from following method: earlier with the gelatin fusing, press 1: 0.05～1.0 mass ratio again, in gelatin, add hydroxypropyl methylcellulose, polyvinylpyrrolidone or water-soluble chitosan, stir.
2. the clear medicament slow release soft capsule of heart and brain according to claim 1 is characterized in that dispersant is a kind of in polyvinylpyrrolidone, carbopol, the Cera Flava.
3. the clear medicament slow release soft capsule of heart and brain according to claim 1 is characterized in that diluent is a kind of in soybean oil, Semen Maydis oil, the Oleum Arachidis hypogaeae semen.
4. the clear medicament slow release soft capsule of heart and brain according to claim 1, the weight part ratio that it is characterized in that said sustained release coating material is 3～6 parts.
5. the clear medicament slow release soft capsule of heart and brain according to claim 1 is characterized in that consumption part ratio of the clear active constituents of medicine of heart and brain, sustained release coating material, dispersant is 4.15: 3～4: 1～2.
6. the clear medicament slow release preparation of soft capsule of heart and brain method is characterized in that it may further comprise the steps:
(a) press mass ratio, take by weighing active constituents of medicine: 390 parts of safflower oils, 3 parts of Borneolum Syntheticums, 7 parts of vitamin e1s, vitamin B
65 parts;
(b) capsule 's content comprises the raw material of following weight part ratio: 0.5～3 part of 4.15 parts of active constituents of medicine, 2～8 parts of sustained release coating materials, dispersant or diluent;
Wherein the sustained release coating material is the mixture of a kind of or the two arbitrary proportion in Polyethylene Glycol, the glyceryl monostearate; Dispersant is that polyethylene adjoins a kind of in pyrrolidone, sheet POP, the Cera Flava, and diluent is a kind of in soybean oil, Semen Maydis oil, the Oleum Arachidis hypogaeae semen;
(c) safflower oil and the other drug active component of 1/2～2/3 in the active constituents of medicine being measured grinds, mixing; With the safflower oil of surplus and sustained release coating material and dispersant or diluent grinds, mixing; With the two mixing, cross 80～100 mesh sieves again, process capsule 's content;
(d) make each softgel shell: earlier with the gelatin fusing, press 1: 0.05～1.0 mass ratio again, in gelatin, add hydroxypropyl methylcellulose, polyvinylpyrrolidone or water-soluble chitosan, stir;
(e) with above-mentioned softgel shell with content compacting or drip and be made as soft capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102639095A CN102106891B (en) | 2009-12-25 | 2009-12-25 | Cardio-cerebral refreshing sustained-release soft capsules and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102639095A CN102106891B (en) | 2009-12-25 | 2009-12-25 | Cardio-cerebral refreshing sustained-release soft capsules and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102106891A CN102106891A (en) | 2011-06-29 |
| CN102106891B true CN102106891B (en) | 2012-11-07 |
Family
ID=44171247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102639095A Active CN102106891B (en) | 2009-12-25 | 2009-12-25 | Cardio-cerebral refreshing sustained-release soft capsules and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102106891B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102824326A (en) * | 2012-09-27 | 2012-12-19 | 中国药科大学 | Novel stable sustained-release soft capsule and preparation method thereof |
| CN114272280B (en) * | 2021-12-30 | 2022-11-18 | 神威药业集团有限公司 | Extraction method of safflower oil and Xinnaoqing soft capsule |
-
2009
- 2009-12-25 CN CN2009102639095A patent/CN102106891B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 国家药品监督管理局编.心脑清软胶囊.《国家药品中药标准》.2002,GJN─304. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102106891A (en) | 2011-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102325526B (en) | Extend the pharmaceutical preparation of release | |
| KR100493836B1 (en) | Pharmaceutical Compositions Comprising Oxcarbazepine | |
| JP5105685B2 (en) | Pharmaceuticalization of thyroid hormone | |
| CN109223725A (en) | For with the pharmaceutical composition containing dimethyl fumarate of low daily dose application | |
| EA004872B1 (en) | beta-CARBOLINE PHARMACEUTICAL COMPOSITIONS | |
| CN105935358B (en) | One seed sand library is than bent Valsartan sustained release agent and preparation method thereof | |
| KR930008956B1 (en) | Process for preparing preparation of sustained release of ibuprofen | |
| AU2017215530A1 (en) | Galenic formulations of organic compounds | |
| CN105232525A (en) | Hypolipidemic drug combination and application thereof | |
| CN103908443A (en) | Propafenone hydrochloride sustained-release capsule and preparation method thereof | |
| CN108042503A (en) | A kind of efficient andrographolide enteric coatel tablets and preparation method | |
| CN102106891B (en) | Cardio-cerebral refreshing sustained-release soft capsules and preparation method thereof | |
| CN1320881C (en) | Compound preparation of Jianganling for liver and its making method | |
| JP7448275B2 (en) | Orbit Azin Fumarate Enteric Coated Pellets, Method of Preparation and Use thereof | |
| CN109646417A (en) | A kind of Trimetazidine sustained release tablets and preparation method thereof | |
| CN106924205A (en) | A kind of sustained release preparation containing Baricitinib | |
| CN102247366A (en) | Medicinal composition comprising quick-release pellets containing Enalapril or Enalapril-acid addition salt and slow-release pellets containing Felodipine | |
| CN104382882B (en) | A kind of Zaleplon dipulse release capsule of non-TCP friendly flow and preparation method thereof | |
| CA2437762C (en) | Emulsions as solid dosage forms for oral administration | |
| CN102188388A (en) | Diclofenac sodium sustained-release pellet preparation and preparation method thereof | |
| CN110339191A (en) | Purposes of the ginkgoterpene lactone in the drug of preparation prevention and/or treatment polycythemia vera | |
| CN100387229C (en) | Amiodarone hydro chloride dispensible tablet, and its preparing method | |
| CN100525770C (en) | Oral compound slow-released pharmaceutics containing theine and salmol active constituent and preparation process thereof | |
| CN100370969C (en) | Chinese materia medica preparation for treating dysmenorrhea of women | |
| CN104586810B (en) | A kind of slow-releasing acipimox tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 051430 Hebei province Luancheng County South Pharmaceutical Company Limited Applicant after: China Shineway Pharmaceutical Group Co., Ltd. Address before: 051430 Hebei province Luancheng County South Pharmaceutical Company Limited Applicant before: Shineway Pharmaceutical Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SHINEWAY PHARMACEUTICAL CO., LTD. TO: SHINEWAY PHARMACEUTICAL GROUP LIMITED |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |